"These studies proved for the first time that hyponatremia, which is associated with poor outcomes, can be treated effectively with an oral drug that has no significant side effects," said Mihai Gheorghiade, M.D., professor of medicine at Northwestern University's Feinberg School of Medicine, who presented the results of the studies at the AHA meeting.
Hyponatremia is a relatively common electrolyte disorder. It affects a wide spectrum of patients including those with liver problems, heart failure and the elderly. It also may affect marathon runners.
Occurring in 15 to 20 percent of hospitalized patients with heart failure, hyponatremia is the opposite of dehydration. Known as "water intoxication," the condition occurs when serum sodium concentration in the blood falls to dangerously low levels causing cells in the body to stop excreting water. Normal serum sodium levels are between 135 and 145 millimoles per liter (mmol/L). Hyponatremia occurs when serum concentration drops to less than 135 mmol/L. In severe cases, it can lead to cerebral edema and even death.
Yet current therapies for hyponatremia are often ineffective and poorly tolerated. The two SALT studies will be published in the November 16 issue of the New England Journal of Medicine and presented at the AHA meeting offer promising information.
Robert Schrier, M.D., professor of medicine of the University of Colorado, Denver, and Gheorghiade and their colleagues at other institutions, found that tolvaptan, a V2-receptor antagonist developed by Otsuka Pharmaceutical Co., Ltd. and Otsuka Maryland Research Institute, Inc., began to improve patients' serum sodium levels almost immediately.
"This easy-to-administer oral drug begins to normalize serum sodium within hours. The normalization is sustained during long-term therapy," Dr. Gheorghiade said. "It is also important to note that tolvaptan was associated with an improvement in mental performance. This is important since cognition can decrease as a result of low serum sodium."
The SALT-1 and SALT-2 studies (Sodium Assessment with Increasing Levels of Tolvaptan) looked at 443 patients in the U.S. and several international sites. During the trial, about half the patients were put on the tolvaptan regimen, the other half on placebo. In both studies, patients assigned to tolvaptan had higher serum sodium concentrations at day 4 and day 30 than those in the placebo group. During the week after discontinuing the tolvaptan, hyponatremia recurred in patients.
SALT-1 and SALT-2 were identical prospective, multicenter, randomized, double-blind placebo-controlled efficacy studies. SALT-1 was conducted at 42 sites in the U.S., SALT-2 at 50 international sites.
Marla Paul | EurekAlert!
New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg
Disarray in the brain
18.12.2017 | Universität zu Lübeck
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
17.01.2018 | Ecology, The Environment and Conservation
17.01.2018 | Physics and Astronomy
17.01.2018 | Awards Funding